Picture loading failed.

Anti-IL5RA therapeutic antibody (Pre-made Benralizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody medication which is developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[2][3]

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-058-1mg 1mg 3090
GMP-Bios-ab-058-10mg 10mg 21890
GMP-Bios-ab-058-100mg 100mg 148000
GMP-Bios-ab-058-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL5RA therapeutic antibody (Pre-made Benralizumab biosimilar,Whole mAb)
INN Name Benralizumab
TargetIL5RA
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesAstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa
Conditions ApprovedAsthma
Conditions ActiveChronic obstructive pulmonary disease;Nasal polyps;Atopic dermatitis;Churg-Strauss syndrome;Hypereosinophilic syndrome;Rhinosinusitis;Eosinophilic gastroenteritis
Conditions DiscontinuedSkin disorders
Development TechPOTELLIGENT Technology